GO
Loading...

Pfizer Inc

More

  • NEW YORK, Sept 8- Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, was sentenced on Monday to nine years in prison for engaging in what authorities called the most lucrative insider trading scheme in U.S. history. District Judge Paul Gardephe in New York also ordered Martoma, 40, to forfeit $9.3 million.

  • Midday Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 1:36 PM ET

    Baxter International Inc. rose$. 40 or. 5 percent, to $74.60. Bristol-Myers Squibb Co. fell$. 01 or percent, to $51.11. Hospira fell$. 88 or 1.6 percent, to $53.02.

  • Most active New York Stock Exchange-traded stocks Monday, 8 Sep 2014 | 1:36 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. Bank of America Corp. rose 2.1 percent to $16.35 with 92,087,900 shares traded. Boston Scientific Corp. rose 2.6 percent to $12.32 with 33,048,900 shares traded.

  • NY judge sentences ex-trader to 9 years in prison Monday, 8 Sep 2014 | 11:24 AM ET

    NEW YORK— An Ivy League- educated ex-portfolio manager convicted of enabling his firm to earn more than a quarter-billion dollars through insider trading on a promising Alzheimer's drug trial was sentenced Monday to nine years in prison by a judge who said the "staggering" fraud deserved lengthy incarceration.

  • Early Glance: Pharmaceuticals companies Monday, 8 Sep 2014 | 10:34 AM ET

    Baxter International Inc. rose$. 06 or. 1 percent, to $74.26. Bristol-Myers Squibb Co. rose$. 02 or percent, to $51.14. Hospira fell $1.22 or 2.3 percent, to $52.68.

  • Midday Glance: Pharmaceuticals companies Friday, 5 Sep 2014 | 3:45 PM ET

    Baxter International Inc. rose$. 67 or. 9 percent, to $74.38. Bristol-Myers Squibb Co. rose$. 32 or. 6 percent, to $50.87. Hospira rose$. 42 or. 8 percent, to $53.85.

  • Early Glance: Pharmaceuticals companies Friday, 5 Sep 2014 | 10:12 AM ET

    Baxter International Inc. rose$. 39 or. 5 percent, to $74.10. Bristol-Myers Squibb Co. rose$. 08 or. 2 percent, to $50.63. Hospira rose$. 39 or. 7 percent, to $53.82.

  • NEW YORK, Sept 4- A federal judge on Thursday refused to throw out the insider trading conviction of former SAC Capital portfolio manager Mathew Martoma, saying the trial evidence "overwhelmingly demonstrated Martoma's guilt."

  • *Zoetis explores international markets for product. CHICAGO, Sept 3- Zoetis Inc has received a conditional license from the U.S. Department of Agriculture for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.

  • CHICAGO, Sept 3- Zoetis Inc, the world's largest animal-health company, has received a conditional license from the U.S. Agriculture Department for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.

  • Midday movers: CompuWare, Halliburton, Nike & more Tuesday, 2 Sep 2014 | 1:37 PM ET

    Some of Tuesday's midday movers:

  • Weaker healthcare stocks weigh on European equities Tuesday, 2 Sep 2014 | 12:40 PM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- A fall in major healthcare stocks, after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer, pegged back European stock markets on Tuesday. "We wouldn't chase stocks at these levels," said HED Capital head Richard Edwards.

  • BUSINESS-NEWS-SCHEDULE AT 1500 GMT / 11:00 a.m. ET Tuesday, 2 Sep 2014 | 11:02 AM ET

    Dollar General sweetens Family Dollar bid, may go hostile. Dollar General Corp raises its bid for Family Dollar Stores Inc to $9.1 billion, and warns it may turn hostile and appeal directly to shareholders if the new offer is rejected.

  • European equities dip as healthcare stocks weaken Tuesday, 2 Sep 2014 | 10:16 AM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- European shares slipped on Tuesday as major healthcare stocks fell after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer. A 1.8 percent fall at AstraZeneca took the most points off the index.

  • BARCELONA, Sept 2- Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Strict British takeover rules limit what Soriot and other players can say about Pfizer's abortive attempt to buy AstraZeneca and the possibility of a resumption of talks.

  • Public pension funds stay mum on tax inversions Tuesday, 2 Sep 2014 | 8:07 AM ET
    The offices of the California Public Employees' Retirement System (Calpers) are shown in Sacramento, Calif.

    Public pension funds have major stakes in American firms moving overseas to cut their tax bills. But they are saying little about the strategy.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Your first trade for Thursday Wednesday, 27 Aug 2014 | 6:15 PM ET

    The "Fast Money" traders share their final trades of the day.